Genomic Health and Biocartis announce agreement to develop an Idylla(TM) IVD Oncotype DX
Genomic Health and Biocartis announced an exclusive agreement to develop an in vitro diagnostic version of the Oncotype DX Breast Recurrence Score® test on Biocartis' Idylla™ platform that can be performed locally by laboratory partners and in hospitals around the world. September 13, 2017